Global Biological Drug CDMO Market Growth (Status and Outlook) 2025-2031
The global Biological Drug CDMO market size is predicted to grow from US$ 30800 million in 2025 to US$ 66310 million in 2031; it is expected to grow at a CAGR of 13.6% from 2025 to 2031.
Key Features:
- Increasing Demand for Biologics: The rising demand for biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and gene therapies, is a significant driver.
- Cost-Effective Outsourcing: Outsourcing to CDMOs allows pharmaceutical and biotech companies to reduce capital expenditures, mitigate risks, and achieve cost savings.
- Strategic Partnerships and Collaborations: Pharmaceutical and biotech companies increasingly engage in strategic partnerships with CDMOs.
- Investment in Biomanufacturing: CDMOs are investing in expanding their biomanufacturing capacities.
- Rising Demand for Advanced Therapies: The increasing interest and investment in cell and gene therapies have led to a rise in demand for CDMOs offering services in this area.
- Global Presence Expansion: Biopharmaceutical CDMOs are expanding their global presence to cater to the needs of a geographically diverse client base.
- Integrated Solutions: CDMOs are expanding their service offerings to provide integrated solutions covering the entire biopharmaceutical development and manufacturing lifecycle.
Segmentation by Type:
- Cell and Gene Therapies
- Antibodies
- Vaccines
- Other
Segmentation by Application:
- SMBs
- Large Companies
Market by Region:
- Americas
- APAC
- Europe
- Middle East & Africa
Company Coverage:
- Lonza
- Catalent
- Samsung Biologics
- FUJIFILM Diosynth Biotechnologies
- Boehringer Ingelheim
- WuXi Biologics
- Recipharm
- Thermo Fisher Scientific
- AGC Biologics
- Rentschler Biopharma
- KBI Biopharma
- Siegfried
- Aenova Group
- GenScript
- ProBioGen
- Northway Biotech
- 3P Biopharmaceuticals
Key Questions Addressed in this Report:
Frequently Asked Questions
Biological Drug CDMO report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Biological Drug CDMO report is categorised based on following features:
- Global Market Players
- Geopolitical regions
- Consumer Insights
- Technological advancement
- Historic and Future Analysis of the Market
Biological Drug CDMO report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.